Last update 20 Mar 2025

YFQLXB-UC01

Overview

Basic Info

Drug Type
Biological products
Synonyms
Target-
Action-
Mechanism-
Therapeutic Areas
Digestive System DisordersRespiratory DiseasesOther Diseases
Active Indication
Decompensated cirrhosis of liverHematopoietic stem cell transplantationAcute-On-Chronic Liver Failure+ [1]
Inactive Indication-
Originator Organization
Shandong Qilu Cell Therapy Engineering Technology Co., Ltd.Shandong Qilu Cell Therapy Engineering Technology Co., Ltd.
Active Organization
Shandong Qilu Cell Therapy Engineering Technology Co., Ltd.Shandong Qilu Cell Therapy Engineering Technology Co., Ltd.
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with YFQLXB-UC01
CTR20241765
/ Not yet recruitingPhase 1/2
一项评价YFQLXB-UC01注射液静脉输注治疗失代偿期肝硬化的安全性、耐受性及有效性临床试验
[Translation] A clinical trial to evaluate the safety, tolerability and efficacy of intravenous infusion of YFQLXB-UC01 injection in the treatment of decompensated liver cirrhosis
100 Clinical Results associated with YFQLXB-UC01
Login to view more data
100 Translational Medicine associated with YFQLXB-UC01
Login to view more data
100 Patents (Medical) associated with YFQLXB-UC01
Login to view more data
100 Deals associated with YFQLXB-UC01
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Decompensated cirrhosis of liverPhase 2
China
Shandong Qilu Cell Therapy Engineering Technology Co., Ltd.Shandong Qilu Cell Therapy Engineering Technology Co., Ltd.
22 May 2024
Hematopoietic stem cell transplantationIND Approval
China
Shandong Qilu Cell Therapy Engineering Technology Co., Ltd.Shandong Qilu Cell Therapy Engineering Technology Co., Ltd.
03 Mar 2025
Acute-On-Chronic Liver FailureIND Approval
China
Shandong Qilu Cell Therapy Engineering Technology Co., Ltd.Shandong Qilu Cell Therapy Engineering Technology Co., Ltd.
02 Jan 2025
Respiratory Distress Syndrome, AcuteIND Approval
China
Shandong Qilu Cell Therapy Engineering Technology Co., Ltd.Shandong Qilu Cell Therapy Engineering Technology Co., Ltd.
03 Oct 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free